FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 729, 2025

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-12934		01-0382980
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

56 Evergreen Drive Portland, Maine		04103
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 207-878-2770

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the Registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ICCC		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02~~. Results~~ Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnAs ~~October~~previously 7,disclosed ~~2025~~in ~~ImmuCell~~the ~~Corporation~~Company’s (Current Report on Form 8-K filed on September 30, 2025, the "Company") ~~issued~~elected aOlivier ~~press~~te ~~release~~Boekhorst ~~announcing~~to serve as its ~~preliminary~~President and Chief Executive Officer starting on November 1, ~~unaudited~~2025. As ~~product~~of ~~sales~~that ~~for~~date, Michael F. Brigham stepped down as President, CEO, Secretary, and Treasurer and assumed the ~~quarter~~position ~~ended~~of ~~September~~Special 30Advisor to the CEO. In connection with the foregoing changes, the Company’s Board of Directors voted on October 29, 2025. ~~The~~to ~~full~~expand ~~text~~the size of the ~~press~~Board ~~release~~from ~~issued~~seven indirectors ~~connection~~to ~~with~~nine directors, and to elect Mr. te Boekhorst and Timothy C. Fiori (the ~~announcement~~Company’s isChief ~~attached~~Financial Officer) as ~~Exhibit~~directors. The 99Company’s Board of Directors also voted to elect Mr.1 Fiori as Secretary and Treasurer of the Company to ~~this~~fill ~~Current~~the ~~Report~~vacancies oncreated ~~Form~~by ~~8-K~~Mr. Brigham’s resignation.

The ~~information~~Company’s ~~shall~~compensatory ~~not~~arrangements bewith ~~deemed~~Mr. ~~"filed"~~te ~~for~~Boekhorst ~~purposes~~and ofMr. ~~Section~~Fiori 18were ofpreviously ~~the~~disclosed ~~Securities~~in ~~Exchange~~the ~~Act~~Company’s ofCurrent ~~1934~~Reports ~~(the~~on ~~"Exchange~~Form ~~Act")~~8-K orfiled ~~otherwise~~on ~~subject~~September to30, ~~liabilities~~2025, ofand ~~that~~April ~~section~~7, ~~nor~~2025, ~~shall~~respectively. Neither itMr. bete ~~deemed~~Boekhorst ~~incorporated~~nor byMr. ~~reference~~Fiori inhave been named to any ~~filing~~committees ~~under~~of the ~~Securities~~Company’s ~~Act~~Board of ~~1933~~Directors. The orCompany ~~the~~is ~~Exchange~~not ~~Act,~~aware ~~except~~of asany ~~expressly~~transaction ~~set~~involving ~~forth~~Mr. byte ~~specific~~Boekhorst ~~reference~~or inMr. ~~such~~Fiori ~~filing~~requiring disclosure under Item 404(a) of Regulation S-K.

~~Item~~A 9copy of the press release announcing the expansion of the Company’s Board of Directors, the election of Mr.01 te Boekhorst as a director, and the election of Mr. ~~Financial~~Fiori ~~Statements~~as a director, Secretary, and ~~Exhibits~~Treasurer is furnished as Exhibit 99.1.

Item 9.01. Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1	Press Release of the Company dated ~~October~~November 74, 2025.
104	Cover page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUCELL CORPORATION
Date: October 7, 2025	By:	/s/ Michael F. Brigham
Date: November 4, 2025	By:	/s/ Timothy C. Fiori
		Michael F. Brigham
		President, Chief Executive Officer and Principal Financial Officer
Date: October 7, 2025	By:	/s/ Timothy C. Fiori
		Timothy C. Fiori
		Chief Financial Officer

Exhibit Index

Exhibit No.		Description
99.1		Press Release of the Company dated ~~October~~November 7,4 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Filing Compare · IMMUCELL CORP /DE/